Format

Send to

Choose Destination
Radiat Oncol. 2015 May 27;10:118. doi: 10.1186/s13014-015-0421-9.

Radiotherapy for asymptomatic brain metastasis in epidermal growth factor receptor mutant non-small cell lung cancer without prior tyrosine kinase inhibitors treatment: a retrospective clinical study.

Liu S1,2,3, Qiu B4,5,6, Chen L7,8,9, Wang F10,11,12, Liang Y13,14,15, Cai P16,17,18, Zhang L19,20,21, Chen Z22,23,24, Liu S25,26,27, Liu M28,29,30, Liu H31,32,33.

Author information

1
State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangzhou, 510060, China. liusr@sysucc.org.cn.
2
Guangdong Esophogeal Cancer Research Institute, Guangzhou, China. liusr@sysucc.org.cn.
3
Department of Radiation Oncology, Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China; Collaborative Innovation Center for Cancer Medicine, Guangzhou, 510060, China. liusr@sysucc.org.cn.
4
State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangzhou, 510060, China. qiubo@sysucc.org.cn.
5
Guangdong Esophogeal Cancer Research Institute, Guangzhou, China. qiubo@sysucc.org.cn.
6
Department of Radiation Oncology, Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China; Collaborative Innovation Center for Cancer Medicine, Guangzhou, 510060, China. qiubo@sysucc.org.cn.
7
State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangzhou, 510060, China. chenlk@sysucc.org.cn.
8
Guangdong Esophogeal Cancer Research Institute, Guangzhou, China. chenlk@sysucc.org.cn.
9
Department of Medical Oncology, Sun Yat-sen University Cancer Center, Guangzhou, China. chenlk@sysucc.org.cn.
10
State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangzhou, 510060, China. wangf@sysucc.org.cn.
11
Guangdong Esophogeal Cancer Research Institute, Guangzhou, China. wangf@sysucc.org.cn.
12
Department of Molecular Diagnosis, Sun Yat-sen University Cancer Center, Guangzhou, China. wangf@sysucc.org.cn.
13
State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangzhou, 510060, China. liangying@sysucc.org.cn.
14
Guangdong Esophogeal Cancer Research Institute, Guangzhou, China. liangying@sysucc.org.cn.
15
Department of Medical Oncology, Sun Yat-sen University Cancer Center, Guangzhou, China. liangying@sysucc.org.cn.
16
State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangzhou, 510060, China. caipq@sysucc.org.cn.
17
Guangdong Esophogeal Cancer Research Institute, Guangzhou, China. caipq@sysucc.org.cn.
18
Department of Radiology, Sun Yat-sen University Cancer Center, Guangzhou, China. caipq@sysucc.org.cn.
19
State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangzhou, 510060, China. zhangli@sysucc.org.cn.
20
Guangdong Esophogeal Cancer Research Institute, Guangzhou, China. zhangli@sysucc.org.cn.
21
Department of Medical Oncology, Sun Yat-sen University Cancer Center, Guangzhou, China. zhangli@sysucc.org.cn.
22
State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangzhou, 510060, China. christyfeel@hotmail.com.
23
Guangdong Esophogeal Cancer Research Institute, Guangzhou, China. christyfeel@hotmail.com.
24
Department of Radiation Oncology, Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China; Collaborative Innovation Center for Cancer Medicine, Guangzhou, 510060, China. christyfeel@hotmail.com.
25
State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangzhou, 510060, China. liushil@sysucc.org.cn.
26
Guangdong Esophogeal Cancer Research Institute, Guangzhou, China. liushil@sysucc.org.cn.
27
Department of Radiation Oncology, Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China; Collaborative Innovation Center for Cancer Medicine, Guangzhou, 510060, China. liushil@sysucc.org.cn.
28
State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangzhou, 510060, China. liumzh@sysucc.org.cn.
29
Guangdong Esophogeal Cancer Research Institute, Guangzhou, China. liumzh@sysucc.org.cn.
30
Department of Radiation Oncology, Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China; Collaborative Innovation Center for Cancer Medicine, Guangzhou, 510060, China. liumzh@sysucc.org.cn.
31
State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangzhou, 510060, China. liuhui@sysucc.org.cn.
32
Guangdong Esophogeal Cancer Research Institute, Guangzhou, China. liuhui@sysucc.org.cn.
33
Department of Radiation Oncology, Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China; Collaborative Innovation Center for Cancer Medicine, Guangzhou, 510060, China. liuhui@sysucc.org.cn.

Abstract

BACKGROUND:

Non-small cell lung cancer (NSCLC) with brain metastasis (BM) harboring an epidermal growth factor receptor (EGFR) mutation shows good response to tyrosine kinase inhibitors (TKIs). This study is to assess the appropriate timing of brain radiotherapy (RT) for asymptomatic BM in EGFR mutant NSCLC patients.

METHODS:

There were 628 patients diagnosed with EGFR mutant NSCLC between October 2005 and December 2011. Treatment outcomes had been retrospectively evaluated in 96 patients with asymptomatic BM without prior TKI treatment. 39 patients received first-line brain RT, 23 patients received delayed brain RT, and 34 patients did not receive brain RT.

RESULTS:

With a median follow-up of 26 months, the 2-year OS was 40.6 %. Univariate analyses revealed that ECOG performance status (p = 0.006), other distant metastases (p = 0.002) and first line systemic treatment (p = 0.032) were significantly associated with overall survival (OS). Multivariate analyses revealed that other sites of distant metastases (p = 0.030) were prognostic factor. The timing of brain RT was not significantly related to OS (p = 0.246). The 2-year BM progression-free survival (PFS) was 26.9 %. Brain RT as first-line therapy failed to demonstrate a significant association with BM PFS (p = 0.643).

CONCLUSIONS:

First-line brain RT failed to improve long-term survival in TKI-naïve EGFR mutant NSCLC patients with asymptomatic BM. Prospective studies are needed to validate these clinical findings.

PMID:
26014133
PMCID:
PMC4490723
DOI:
10.1186/s13014-015-0421-9
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for BioMed Central Icon for PubMed Central
Loading ...
Support Center